Capstone Therapeutics (NASDAQ:CAPS) vs. Custom Truck One Source (NYSE:CTOS) Critical Analysis

Custom Truck One Source (NYSE:CTOS) and Capstone Therapeutics (NASDAQ:CAPS) are both industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Custom Truck One Source and Capstone Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Custom Truck One Source	2	1	4	1	2.50
Capstone Therapeutics	1	0	0	0	1.00

Custom Truck One Source presently has a consensus price target of $11.21, indicating a potential upside of 6.49%. Given Custom Truck One Source’s stronger consensus rating and higher possible upside, analysts clearly believe Custom Truck One Source is more favorable than Capstone Therapeutics.

Insider & Institutional Ownership

90.1% of Custom Truck One Source shares are held by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are held by institutional investors. 4.7% of Custom Truck One Source shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Custom Truck One Source has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.52, indicating that its share price is 252% less volatile than the S&P 500.

Valuation & Earnings

This table compares Custom Truck One Source and Capstone Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Custom Truck One Source	$1.94 billion	1.23	-$31.05 million	$0.09	117.01
Capstone Therapeutics	$48.11 million	0.10	-$21.23 million	($3.37)	-0.09

Capstone Therapeutics has lower revenue, but higher earnings than Custom Truck One Source. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Custom Truck One Source, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Custom Truck One Source and Capstone Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Custom Truck One Source	1.05%	2.66%	0.61%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Summary

Custom Truck One Source beats Capstone Therapeutics on 13 of the 15 factors compared between the two stocks.

About Custom Truck One Source

Custom Truck One Source, Inc. provides specialty equipment rental and sale services to the electric utility transmission and distribution, telecommunications, rail, forestry, waste management, and other infrastructure-related industries in the United States and Canada. The company operates through three segments: Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). The ERS segment owns new and used specialty equipment, including truck-mounted aerial lifts, cranes, service trucks, dump trucks, trailers, digger derricks, and other machinery and equipment. The TES segment offers new equipment for sale to be used for end-markets, which can be modified to meet customers specific needs. The APS segment provides truck and equipment maintenance and repair services; and rents and sells specialized tools, including stringing blocks, insulated hot stick, and rigging equipment, as well as sale of specialized aftermarket parts. The company was formerly known as Nesco Holdings, Inc. and changed its name to Custom Truck One Source, Inc. in April 2021. Custom Truck One Source, Inc. was founded in 1988 and is headquartered in Kansas City, Missouri.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.